Development of Advanced Drug Delivery Systems for Respiratory Diseases

De Rubis, Gabriele

Development of Advanced Drug Delivery Systems for Respiratory Diseases

De Rubis, Gabriele

Permalink

Publication Type:: Thesis
Issue Date:: 2023

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download thesisAdobe PDF (33.24 MB)

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	De Rubis, Gabriele
dc.date.accessioned	2023-11-27T02:59:00Z
dc.date.available	2023-11-27T02:59:00Z
dc.date.issued	2023
dc.identifier.uri	http://hdl.handle.net/10453/173581
dc.description	University of Technology Sydney. Graduate School of Health.	en_US.UTF-8
dc.description.abstract	This thesis addresses the significant health burden posed by Chronic Respiratory Disorders (CRDs), including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer. These diseases share common pathophysiological mechanisms including inflammation, oxidative stress, airway remodelling, and are major contributors to global mortality, collectively causing about 5 million annual deaths. Current treatments have limited efficacy and severe adverse effects. Promising therapies include phytoceuticals such as berberine and Agarwood, and modern nucleic acid-based therapies. However, their clinical application is limited by challenges like poor solubility and unfavourable pharmacokinetics. In this thesis, advanced drug delivery systems (ADDS) are tested in vitro to overcome these limitations. The thesis presents three main chapters: 1. Encapsulation of a NFkB-inhibiting decoy oligodeoxynucleotide in nanoparticles for lung cancer, showing significant inhibition of proliferation, migration, and colony formation. 2. Formulation of an Agarwood oil nanoemulsion, demonstrating potent anti-inflammatory and antioxidant activity in a COPD model. 3. Encapsulation of berberine in liquid crystalline nanoparticles, mitigating TGF-β-induced airway remodelling in bronchial cells. Overall, the findings of the present thesis underscore the enormous potential of ADDS to improve drug efficacy, offering a promising avenue for effective treatment and management of respiratory diseases.	en_US.UTF-8
dc.format	Thesis (PhD)
dc.language.iso	en_US	en_US.UTF-8
dc.relation	https://opus.lib.uts.edu.au/bitstream/10453/173581/1/thesis.pdf
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	The author owns the copyright in this thesis including all reproduction and reuse rights for the work. The work may not be altered without the permission of the copyright owner. Attribution is essential when quoting or paraphrasing from this thesis.
dc.rights	© 2023 Gabriele De Rubis
dc.rights	au.edu.uts.lib/cph
dc.title	Development of Advanced Drug Delivery Systems for Respiratory Diseases	en_US.UTF-8
dc.type	Thesis
utslib.copyright.status	open_access	*

Abstract:

This thesis addresses the significant health burden posed by Chronic Respiratory Disorders (CRDs), including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer. These diseases share common pathophysiological mechanisms including inflammation, oxidative stress, airway remodelling, and are major contributors to global mortality, collectively causing about 5 million annual deaths. Current treatments have limited efficacy and severe adverse effects. Promising therapies include phytoceuticals such as berberine and Agarwood, and modern nucleic acid-based therapies. However, their clinical application is limited by challenges like poor solubility and unfavourable pharmacokinetics. In this thesis, advanced drug delivery systems (ADDS) are tested in vitro to overcome these limitations. The thesis presents three main chapters: 1. Encapsulation of a NFkB-inhibiting decoy oligodeoxynucleotide in nanoparticles for lung cancer, showing significant inhibition of proliferation, migration, and colony formation. 2. Formulation of an Agarwood oil nanoemulsion, demonstrating potent anti-inflammatory and antioxidant activity in a COPD model. 3. Encapsulation of berberine in liquid crystalline nanoparticles, mitigating TGF-β-induced airway remodelling in bronchial cells. Overall, the findings of the present thesis underscore the enormous potential of ADDS to improve drug efficacy, offering a promising avenue for effective treatment and management of respiratory diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/173581